Neal D. Shore, MD, discusses results from the phase 2 ODENZA trial presented at the 2021 ASCO Annual Meeting. The study is a prospective, randomized, open-label, multicenter, crossover, trial that assessed patient preference between darolutamide (Nubeqa) and enzalutamide (Xtandi) in men with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer. Shore is medical director of the Carolina Urologic Research Center.
Enhancing the quality of bladder cancer care in the community setting
August 5th 2023Suzanne Merrill, MD, recaps the BCAN 2023 Think Tank session she co-chaired that covered prehabilitation programs, urinary diversion management, and other focal areas aimed at enhancing the quality of bladder cancer care in the community.
BCAN session to highlight epigenetics and response to immunotherapy in bladder cancer
August 3rd 2023"I'm really optimistic that the session we are conducting will provide some recommendations [and] some ideas that will help us think about utilizing epigenetic therapies in a very evidence-based way," says Ania Woloszynska, PhD.
2 Clarke Drive
Cranbury, NJ 08512